Dissection of the Molecular and Immunological Interaction in Patients With Hepatocellular Carcinoma of Viral and Non-viral Etiologies
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 579
- 试验地点
- 4
- 主要终点
- transcriptomic analysis of immune microenvironment
研究概览
简要总结
This project will clarify the potential interaction between HBV infection and steatosis, and their impact on genetic alterations and tumor immune microenvironment.
详细描述
This study will start with a "training cohort" of the NTUH and NTU Cancer Center patients, consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort. The following studies will be performed: (1) NGS of targeted genes panel using the National Health Research Institutes precision medicine platform; (2) transcriptomic analysis of immune microenvironment using RNA-seq and multiplex immunofluorescence staining; (3) lipotoxic genotyping for SNPs; (4) clinical outcomes of MAFLD vs. non-MAFLD. The genetic and immunological features will be further tested by a "validation cohort", from collaborative hospitals. This project will clarify the potential interaction between HBV infection and steatosis, and their impact on genetic alterations and tumor immune microenvironment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult female or male patients aged ≥20 years.
- •HCC has been histologically confirmed with resection specimen.
- •The surgery should be performed with curative intent after 2015 in the study hospital.
- •Availability of serum HBsAg and Anti-HBc data in the electronic medical record.
- •Availability of imaging data performed within 3 months before the surgery in the electronic medical record. (at least one of the following: computed tomography, magnetic resonance imaging, abdominal sonography).
- •Informed consent is obtained. Willingness to provide the residual operative slides and medical records.
排除标准
- •Fibrolamellar HCC, sarcomatoid HCC, or a mixture of cholangiocarcinoma and HCC
- •Exclusion of HCV patients (Anti-HCV positive)
- •Inability to cooperate by providing a complete medical history.
结局指标
主要结局
transcriptomic analysis of immune microenvironment
时间窗: 2 Years
using RNA-seq and multiplex immunofluorescence staining
lipotoxic genotyping for SNPs
时间窗: 2 years
lipotoxic genotyping for SNPs
clinical outcomes of MAFLD vs. non-MAFLD.
时间窗: 2 years
clinical outcomes of MAFLD vs. non-MAFLD.
次要结局
未报告次要终点
